We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microchip Technology Screens for More Than 1000 Molecules

By LabMedica International staff writers
Posted on 06 Aug 2009
Scientists have developed technology to perform over a thousand chemical reactions at once on a stamp-size, PC-controlled microchip.

The technology, which is based on microfluidics, utilized miniaturized devices to automatically handle and channel tiny amounts of liquids and chemicals invisible to the eye. More...
The chemical reactions were performed using in situ click chemistry, and analyzed using mass spectrometry.

A thousand cycles of complex processes, including controlled sampling and mixing of a library of reagents and sequential microchannel rinsing, all took place on the microchip device and were completed in a few hours. Developed by a University of California, Los Angeles (UCLA; Los Angeles, CA, USA) team, the technology is restricted to analyzing the reaction results offline, but the aim is to automate this aspect of the work also. It could accelerate the identification of potential drug candidates for treating diseases like cancer.

The team intends to utilize the technology for diagnostic screening reactions in which chemicals and material samples are in limited supply; e.g., protein enzymes such as kinases that play critical roles in the malignant transformation of cancer. According to the scientists, the technology will open up many areas for biologic and medicinal study.

"The precious enzyme molecules required for a single in situ click reaction in a traditional lab now can be split into hundreds of duplicates for performing hundreds of reactions in parallel, thus revolutionizing the laboratory process, reducing reagent consumption and accelerating the process for identifying potential drug candidates," said study author Prof. Hsian-Rong Tseng, scientist at UCLA's Crump Institute for Molecular Imaging, associate professor molecular and medical pharmacology at the David Geffen School of Medicine at UCLA, and a member of the California NanoSystems Institute at UCLA.

The Study appeared online in the August 2009 edition of Science Daily.

Related Links:
University of California, Los Angeles
Science Daily


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.